Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 53.80
-0.60 (-1.10%)
Feb 20, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Employees
Basilea Pharmaceutica AG had 180 employees as of June 30, 2025.
Employees
180
Change
n/a
Growth
n/a
Revenue / Employee
1.29M CHF
Profits / Employee
223.56K CHF
Market Cap
668.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 180 | - | - |
| Dec 31, 2024 | 164 | 17 | 11.56% |
| Dec 31, 2023 | 147 | 6 | 4.26% |
| Dec 31, 2022 | 141 | -13 | -8.44% |
| Dec 31, 2021 | 154 | -3 | -1.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 153 |
| Santhera Pharmaceuticals Holding AG | 79 |
| BioVersys AG | 29 |
| Newron Pharmaceuticals | 22 |
| Xlife Sciences AG | 17 |
| Addex Therapeutics | 2 |
Basilea Pharmaceutica AG News
- 2 days ago - Basilea Pharmaceutica Ltd (BPMUF) Full Year 2025 Earnings Call Highlights: Strong Revenue ... - GuruFocus
- 2 days ago - Full Year 2025 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript - GuruFocus
- 2 days ago - Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Basilea Pharmaceutica AG 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Basilea Pharmaceutica AG GAAP EPS of CHF 3.14, revenue of CHF 232.4M - Seeking Alpha
- 3 days ago - Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance - GlobeNewsWire
- 11 days ago - Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea - GlobeNewsWire
- 5 weeks ago - Basilea Pharmaceutica Partners With INCATE To Advance Antibacterial And Antifungal Innovation - Nasdaq